JLJingwen Liu

Jingwen Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jingwen Liu has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Michael J. Spence

    Mountain States Medical Research Institute and Department of Veterans Affairs Medical Center|Long Island Jewish Medical Center

    2 shared publications
  • Y. Lynda Zhang

    Mountain States Medical Research Institute and Department of Veterans Affairs Medical Center|Long Island Jewish Medical Center

    2 shared publications
  • C Li

    1 shared publication
  • David S. Grass

    From the Department of Veterans Affairs Medical Center and Mountain States Medical Research Institute, Boise, Idaho (J.L., Y.L.Z., M.J.S., R.E.V.); the Departments of Medicine and Pharmacology, University of Washington (R.E.V.), and Bristol-Myers Squibb Pharmaceutical Research Institute (P.M.W.), Seattle, Wash; and Chrysalis DNX Transgenic Sciences, Princeton, NJ (D.S.G.).

    1 shared publication
  • Fredric B. Kraemer

    VA Palo Alto Health Care System

    1 shared publication
  • L M Boxer

    1 shared publication

Latest Publications

  • Transcriptional suppression of synuclein γ (SNCG) expression in human breast cancer cells by the growth inhibitory cytokine oncostatin M

    by Jingwen Liu, Michael J. Spence, Y. Lynda Zhang, Yangfu Jiang, Yiliang E. Liu, Y. Eric Shi

    Previously, we have shown that synuclein γ (SNCG), a member of the brain protein synuclein family, is highly expressed in human infiltrating breast carcinomas but not expressed in normal or benign breast tissues. The SNCG mRNA was also detected in several human breast cancer cell lines with the highest expression found in H3922, a cell line derived from an infiltrating ductal carcinoma. In this study, we show that expression of SNCG mRNA in H3922 cells is significantly decreased by treating cells with the cytokine oncostatin M (OM) who has a growth-inhibitory effect on these cells. A decrease in SNCG mRNA level can be detected as early as 30 min after OM addition. By 4 h OM treatment, the level of SNCG mRNA was decreased to 70% of control, and by 24 h the mRNA was below detectable level. Western blot analysis further demonstrated the suppression of SNCG protein expression by OM. The level of SNCG protein in H3922 cells was reduced more than 90% by OM after 2 days. Since OM- induced growth inhibition occurs after 3–4 days, the down-regulation of SNCG expression appears to proceed the effect of OM on cell growth. Additional experiments to measure the transcriptional rates of SNCG indicate that the observed OM-induced down-regulation of SNCG mRNA occurs mainly at the transcriptional level. In an attempt to examine the role of SNCG gene in the proliferation of breast cancer cells, SNCG cDNA was stably transfected into MCF-7 cells that do not express endogenous SNCG gene. Examination of cell growth under anchorage-dependent and anchorage-independent conditions demonstrates that over expression of SNCG gene significantly stimulated the growth of MCF-7 cells both in monolayer culture and in soft agar. These data together suggest that SNCG may play a role in cell proliferation.


  • Open Access

    Identification of a Novel Sterol-independent Regulatory Element in the Human Low Density Lipoprotein Receptor Promoter

    by Jingwen Liu, Thomas E. Ahlborn, Michael R. Briggs, Fredric B. Kraemer


    • 1 October 1999
      • Vol. 10  (10) , 677-83

    The expression of p53 tumor suppressor gene in breast cancer cells is down-regulated by cytokine oncostatin M.

    by J Liu, C Li, T E Ahlborn, M J Spence, L Meng, L M Boxer

    Previously (J. Liu, et al., Cell Growth Differ., 8: 667-676, 1997), we showed that oncostatin M (OM), a cytokine produced by activated T cells and macrophages, inhibited the proliferation of breast cancer cells derived from solid tumors and malignant effusions. OM-treated cells showed reduced growth rates and differentiated phenotypes. Because the p53 tumor suppressor protein plays an important role in cellular proliferation, we examined p53 protein expression in three OM-responsive breast cancer cell lines, MCF-7, MDA-MB231, and H3922. Western blot analysis showed that p53 protein levels in all three of the cell lines were decreased by OM treatment. Reduction of p53 protein was detected after 1 day of OM treatment and reached maximal suppression of 10-20% of control after 3 days in H3922 and 40% of control after 4 days in MCF-7 cells. A comparison of p53 mRNA in OM-treated cells versus untreated control cells showed that exposure to OM reduced the steady-state levels of p53 mRNA transcripts to an extent similar to that of the p53 protein levels. This observation suggests that the effect of OM on p53 protein expression does not occur at the posttranslational level. Nuclear run-on assays verified that OM decreased the number of actively transcribed p53 mRNAs, which suggests a transcriptional regulatory mechanism. The effect of OM on p53 expression seems to be mediated through the extracellular signal-regulated kinase (ERK) pathway, inasmuch as the inhibition of ERK activation with a specific inhibitor (PD98059) to the ERK upstream kinase mitogen/extracellular-regulated protein kinase kinase abrogated the OM inhibitory activity on p53 expression in a dose-dependent manner. In addition to OM, we showed that the p53 protein expression in MCF-7 cells was also decreased by phorbol 12-myristate 13-acetate treatment (PMA). Because both OM and PMA induce MCF-7 cells to differentiate, our data suggest that p53 expression in breast cancer cells is down-regulated during the differentiation process.


  • Liver LDL Receptor mRNA Expression Is Decreased in Human ApoB/CETP Double Transgenic Mice and Is Regulated by Diet as Well as the Cytokine Oncostatin M

    by Jingwen Liu, Y. Lynda Zhang, Michael J. Spence, Robert E. Vestal, Philip M. Wallace, David S. Grass

    We have investigated liver LDL receptor mRNA expression in nontransgenic, human cholesteryl ester transfer protein (CETP) transgenic, and human apolipoprotein (Apo) B/CETP double transgenic mice fed a normal chow diet and a high fat, high cholesterol diet (HFHC). Three weeks of HFHC feeding increased total serum cholesterol 1.5-fold in the nontransgenic, 3.1-fold in the CETP transgenic, and 3.4-fold in the ApoB/CETP double transgenic mice. To examine the liver LDL receptor mRNA expression among the different groups of mice fed the normal diet or fed the HFHC diet, we developed a quantitative reverse-transcribed polymerase chain reaction assay in which the LDL receptor mRNA level was normalized with the β-actin mRNA. The results show that on the normal chow diet, the LDL receptor mRNA expression levels were lower in the ApoB/CETP mice than in the nontransgenic mice and the human CETP transgenic mice. Liver LDL receptor gene expression was lower in all groups of mice fed the HFHC diet, with the lowest level of expression in the ApoB/CETP mice. Similar results were obtained by Northern blot analysis. In addition, we have previously shown that the cytokine oncostatin M (OM) increases LDL receptor gene expression in HepG2 cells. In this study, we used the ApoB/CETP mice as the model system to examine the in vivo activity of OM on liver LDL receptor gene expression. Our data show that OM increased the level of liver LDL receptor mRNA up to 80% to 90% when the animals were fed the HFHC diet. The results from these studies demonstrate that the expression of the liver LDL receptor in the ApoB/CETP mice is suppressed compared with nontransgenic mice and that the expression of the hepatic LDL receptor gene in these mice is subjected to the normal cholesterol feedback regulation. In addition, LDL receptor gene expression in these mice is also inducible by a positive regulator.